PURMX has created a novel discovery platform, discovery of microRNAs optimized for safety and efficacy. In a Phase I clinical trial, we are evaluating our lead product, MIRX002 (miR-3140-3p), an optimized microRNA. MIRX002 targets multiple pathways involved in malignancies with minimal overlap with normal cellular functions. MIRX002 demonstrated potent anti-tumor activity in multiple animal models and a wide therapeutic window in GLP nonclinical safety.
We look forward to introducing you to PURMX and MIRX002, including our ongoing clinical trial and future development opportunities.
We look forward to introducing you to PURMX and MIRX002, including our ongoing clinical trial and future development opportunities.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
